People with natural immunity to HIV may serve as basis for new vaccine

November 9, 2012 by James Hataway, University of Georgia

(Medical Xpress)—Despite urgent need and tremendous scientific effort, researchers have yet to discover a vaccine for HIV that adequately protects humans from infection. But some people don't need one. For reasons not completely understood, there are individuals who have developed a natural immunity to the virus without any medical intervention.

Now, thanks in part to a five-year $1.3 million grant from the National Institutes of Health, researchers at the University of Georgia in collaboration with researchers at Scripps Research Institute are trying to mimic this in a new vaccine that may one day help stop the disease that infects five million people each year.

"HIV is very good at evading the immune system, but people with natural immunity have that will protect them against most variations of the virus," said Joshua Sharp, an analytical chemist and assistant research scientist in UGA's Research Center. "We want to figure out how to evoke the same kind of in other people."

The average person's immune system will attempt to fight HIV, but normally the virus simply mutates and deflects the attack until it is able to replicate and spread unimpeded.

Sharp's laboratory, along with with Robert Woods' computational chemistry group at the University of Georgia and Dennis Burton's virology group at Scripps Research Institute, is exploring how people with natural immunity to HIV create antibodies that bind with a specific protein on the exterior of the virus called gp120.

Gp120 helps the virus find targets inside the body, latch onto them and invade host cells. Antibodies in people with natural immunity assault this and disrupt its functions. More importantly, the virus cannot mutate to bypass the attack.

"Nature is a beautiful chemistry lab," Sharp said. "What we need to do is take these antibodies that we find in nature, reverse engineer them and make them available to everyone."

Sharp, Woods, and their colleagues will use analytical chemistry tools and computer simulation to develop a clearer idea of how and where these antibodies bind to the , and what is required for scientists to make the same thing happen in a vaccine.

"Essentially, what we're doing is taking snapshots of the protein's outer shell," Sharp said.

Once they know where the antibody binds, researchers can replicate that protein location and try to make the same process happen artificially in someone without natural immunity.

Sharp, Woods, and Burton hope that their new approach will not only result in the long sought-after HIV vaccine but also revolutionize the process of creating vaccines for other diseases.

The human body is a tremendous reservoir for disease fighting tools, he said. In the case of HIV and other important pathogens, it may simply be a matter of understanding and exploiting the natural defenses that have been evolving for millions of years.

Explore further: Insight into HIV immunity may lead to vaccine

Related Stories

Insight into HIV immunity may lead to vaccine

May 6, 2011
(Medical Xpress) -- Latest insights into immunity to HIV could help to develop a vaccine to build antibodies’ defences against the disease, a University of Melbourne study has found.

New HIV vaccine approach targets desirable immune cells

September 1, 2011
Researchers at Duke University Medical Center, Beth Israel Deaconess Medical Center and Harvard Medical School have demonstrated an approach to HIV vaccine design that uses an altered form of HIV's outer coating or envelope ...

Recommended for you

Proof-of-concept HIV immunotherapy study passes Phase 1 safety trial

September 21, 2018
Preliminary results from a phase I clinical trial have demonstrated the safety and tolerability of a cell therapy involving the ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals previously ...

FRESH program combines basic science with social benefits for women at risk of HIV

September 14, 2018
A program established by investigators from the Ragon Institute of Massachusetts General Hospital (MGH), MIT and Harvard is addressing the persistently elevated risk of HIV infection among young women in South Africa from ...

New study finds HIV outbreak in Indiana could have been prevented

September 13, 2018
An HIV outbreak among people who inject drugs in Indiana from 2011 to 2015 could have been avoided if the state's top health and elected officials had acted sooner on warnings, a new study by the Yale School of Public Health ...

Largest study of 'post-treatment controllers' reveals clues about HIV remission

September 13, 2018
Most HIV patients need to take daily anti-retroviral therapy—if they suspend treatment, HIV will rebound within 3-4 weeks. But clinical trials have revealed that a small fraction of patients can stop taking medications ...

Very few sexually active gay and bisexual men use prophylactic drug to prevent HIV transmission, study finds

September 12, 2018
Only 4 percent of sexually active gay and bisexual men in the United States use Truvada, a highly effective medication used to prevent the transmission of HIV, according to the results of a first-of-its-kind study.

Special antibodies could lead to HIV vaccine

September 10, 2018
Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. Researchers from the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.